openPR Logo
Press release

Ulcerative Colitis Market to Reach $4,785 Million by 2023

02-01-2021 07:01 PM CET | Health & Medicine

Press release from: Allied Market Research

Ulcerative Colitis Market

Ulcerative Colitis Market

Advancements in ulcerative colitis treatment modalities has led to the emergence of biologics such as tumor necrosis factors (TNF) in developing drugs. This has led to the shift from traditional therapies towards engineered drugs that has also enhanced the efficacy rate of drugs.

According to a new report published by Allied Market Research, titled, Ulcerative Colitis Market by Disease Type, Route of Administration, and Molecule Type: Global Opportunity Analysis and Industry Forecast, 2017-2023, the global ulcerative colitis market was valued at $4,785 million in 2016, and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023. The mild ulcerative colitis disease type accounted for nearly half of the market share in 2016.

Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/3965

Ulcerative colitis is an inflammatory bowel disease that affects the colon and rectum of the human body. The disease affects people of any age and most commonly it begins during adolescence and early adulthood, but it may also occur later in life. Ulcerative colitis is highly prevalent in the U.S., England, and northern Europe. The most commonly preferred treatment options for ulcerative colitis are traditional medications made of biologics and small molecules.

The prime factors factor that drive global ulcerative colitis market are increase in prevalence of ulcerative colitis globally and rise in R&D activities by key players towards new drug formulations for disease treatment. In addition, increase in patient assistance programs that has raised the demand for branded drugs further fuels the market growth. Untapped emerging economies that lack proper medical assistance are expected to provide numerous opportunities for market expansion.
The oral segment dominated the ulcerative colitis market with half of the market share in 2016, as it is an easy route of administration and immediate destruction of drugs by gastric acid is avoided. The injectable segment is expected to register the highest CAGR of 6.9%.

The moderate disease type segment is expected to witness highest growth rate throughout the forecast period, with a CAGR of 6.8%. This is due the exponential increase in prevalence of ulcerative colitis and lack of awareness in emerging economies coupled with unavailability of proper treatment modalities and drug approvals. This leads to conversion of an ulcerative colitis disease from mild state to moderate state.

For Purchase Enquiry: @ https://www.alliedmarketresearch.com/purchase-enquiry/3965

Key Findings of the Ulcerative Colitis Market:
• The severe disease type segment is anticipated to grow with a CAGR of 6.7% from 2017 to 2023.
• U.S. was the highest shareholder in the North American ulcerative colitis market in 2016, and is poised to retain its lead during the forecast period.
• Biologics registered the highest CAGR of 6.9%.
• India is expected to grow at a significant rate of 7.1%.
• The small molecules segment accounted for half of the share in 2016, registering a CAGR of 6.1%.

In 2016, Asia-Pacific and LAMEA collectively accounted for about two-sevenths share of the market and are expected to continue this trend in the future. This is due to high incidence of ulcerative colitis disease in China, India, and the other developing economies. Moreover, rise in investments towards development of healthcare infrastructure done by key players in the ulcerative colitis treatment field drives growth in the Asia-Pacific region.

The key players operating in the global ulcerative colitis market are Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Co., Sanofi Aventis A/S, AstraZeneca plc, Merck & Co., Inc., InDex Pharmaceuticals Holding AB, Ajinomoto Pharmaceuticals Co., Ltd., and Abbott Laboratories. The other prominent players in the value chain include Avaxia Biologics Inc., BioLineRx Ltd., Celgene Corporation, Mitsubishi Tanabe Pharma Corporation, and Salix Pharmaceuticals, Inc.

Know More @ https://www.alliedmarketresearch.com/ulcerative-colitis-market

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ulcerative Colitis Market to Reach $4,785 Million by 2023 here

News-ID: 2234323 • Views: 250

More Releases from Allied Market Research

High Speed Oven Market Size is Projected Rise $3.6 Billion by 2030, Growing At a …
According to a new report, "High Speed Oven Market by Type, (Built-In and Countertop), End User (Residential and Commercial), and Sales Channel (Hypermarkets/Supermarkets, Specialty Stores, and Online Channels): Global Opportunity Analysis and Industry Forecast, 2021-2030". The global high speed oven market size was valued at $2.3 billion in 2020, and is projected reach $3.6 billion by 2030, registering a CAGR of 4.8% from 2021 to 2030. Access Full Summary: https://www.alliedmarketresearch.com/high-speed-oven-market-A07064 High speed
Intravenous Therapy and Vein Access Market Expected to Reach $37.5 Billion by 20 …
(IV) therapy is one of the most frequently used health care therapies. It is performed in emergency response settings, hospitals, clinics, nursing homes, and, at an individual's home. IV therapy is used for many reasons, including restoration of fluids in dehydrated patients. In patients with severe vomiting and/or diarrhea, especially in children, dehydration can be fast and severe. IV therapy transfers and replaces fluids and electrolytes, providing rest to the
Japan Household Appliance Market Size is Projected to Rise $27,979.0 Million by …
A new report, titled, "Japan Household Appliance Market by Product and Distribution Channel: Opportunity Analysis and Industry Forecast, 2018-2025" The report offers an extensive analysis of changing market trends, key segments, top investment pockets, regional scenario, Porter's Five Forces, and competitive scenario. The Japan household appliance market size was valued at $20,279.9 million in 2017, and is expected to reach $27,979.0 million by 2025, growing at a CAGR of 4.0%
Proteomics Market Expected to Reach $98.1 Billion by 2031
Proteomics Market Size was valued at $23,654.34 million in 2021, and is projected to reach $98,051.83 million by 2031, growing at a CAGR of 15.2% from 2022 to 2031. Proteomics studies the interactions, functions, compositions, and structures of proteins and their cellular activities. Proteomics provides a better understanding of the structure and function of the organism than genomics. It has the capacity to explain questions that were unsolved by genomics,

All 5 Releases


More Releases for Ulcerative

Ulcerative Colitis Market to Obtain Awesome Hike in Revenues
Global ulcerative colitis market was valued at $4,785 million in 2016, and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023. The mild ulcerative colitis disease type accounted for nearly half of the market share in 2016. Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/3965 Ulcerative colitis is an inflammatory bowel disease that affects the colon and rectum of the human body. The disease
Ulcerative Colitis Market - Global Industry Analysis, Size, Forecast 2028
Ulcerative Colitis Market “Ulcerative Colitis-Epidemiology Forecasting Intelligence” report provides a comprehensive analysis of the Ulcerative Colitis epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028. Our epidemiology services include: • Incidence and prevalence • Diagnosis rate, treatment rate and mortality patterns • Epidemiology-based forecasting and disease trends • Size of different patient segments in a
Global Ulcerative Colitis Treatment Market Insights, Forecast to 2025
Market Research Report Store offers a latest published report on Ulcerative Colitis Treatment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 158 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/323101/global-ulcerative-colitis-treatment-market-insights   Anti-inflammatory drugs are often the first
Ulcerative Colitis Market and Forecast Analysis
Boston, MA ReportsWorldwide has announced the addition of a new report title Ulcerative Colitis Market and Forecast Analysis to its growing collection of premium market research reports. Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost layer of the intestinal lining. Ulcerative colitis is a chronic, incurable disease with low mortality that is generally diagnosed
Ulcerative Colitis Market
Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained
Ulcerative Colitis Pipeline Analysis, 2016
Ulcerative colitis is an inflammatory condition of colon, in which ulcer is formed in the colon lining. In ulcerative colitis, inflamed colon develops small number of open lesion, that produce pus and mucous. The abnormal response of the immune system causes inflammation in the colon. The ulcerative colitis pipeline has more than 45 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is